Clinical Trial

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Study acronym: RELATIVITY1093
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
Protocol Amendment History 3 changes
notable Trial sites expanded: 312 -> 320 locations 2026-06-24
notable Trial sites expanded: 299 -> 312 locations 2026-05-21
notable Trial sites expanded: 282 -> 299 locations 2026-05-01
Trial Details
NCT Number NCT06561386
Lead Sponsor Bristol-Myers Squibb
Conditions Non-small Cell Lung Cancer
Enrollment 1,000 participants
Start Date 2024-10-07
Primary Completion 2030-07-30 (estimated)
Study Completion 2032-08-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-20